Andreas Vogler

Techpharma Management AG engages in the provision of services to affiliated firms and the operation of hotels. Its services include the provision of real estate for use, and advice on management, financing and investment issues, as well as the administration of hotels and restaurants, in particular the Hotel Stadthaus, the Hotel Berchtold and the Restaurant Schützenhaus in Burgdorf. The company was founded on May 4, 2000 and is headquartered in Burgdorf, Switzerland.

Baader Helvea AG (Baader Helvea) s the research-based Swiss brokerage subsidiary of Baader Bank AG (XE: BWB) in Germany. Formerly known as Helvea SA, established in 1990, the firm is located in Geneva and specializes in equity research, sales, sales trading, execution and administration, and services institutional clients worldwide, including pension funds, insurance funds, unit trusts, balanced funds and hedge funds. Their core market is Switzerland with a focus on small- and mid-cap companies; however, they also have expertise in European equity especially in those sectors in which Swiss companies operate as global players, such as banking, insurance, healthcare, food manufacturing, chemicals and luxury goods. The firm's research process focuses on company analysis and includes a company visitation program. They aim to identify companies likely to generate superior returns for shareholders and to evaluate sector or company-specific trends.

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Kurma Biofund seeks investment opportunities in life science and biotechnology companies located in Europe. The investments are done in cooperation with medical institutes and universities such as Institut Pasteur and Institut Curie. Its investment size ranges between €0.10 and €6 million.

Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway.

Ki Consulting AG provides management consulting services. The private company is based in Reinach, Switzerland. The Swiss company was founded by Khalid Islam.

Rheoscience A/S develops and manufactures pharmaceutical products. The private company is based in Redovre, Denmark.

Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

Prev AbR LLC develops biologic and beta-lactamase compounds. The private company is based in Bethesda, MD. The company was founded by Khalid Islam.

GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland.

Elion Oncology, Inc. engages in the provision of pharmaceutical services. The company was founded in 2016 and is headquartered in Bethesda, MD.

Esocap AG is a privately funded company based in Basel, Switzerland. The Swiss company's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through the development of a unique and innovative topical drug delivery platform. The company is cooperating with key R&D and industrial partners, including the University of Greifswald, where the Esocap technology was invented by Prof. Werner Weitschies and his team. Esocap has filed several worldwide patents for their technology, which includes a capsule holder and production methods. The CEO of the company is Isabelle Racamier.